Mintz Levin Serves as Counsel to Coley Pharmaceutical Group in its IPO and Concurrent Private Placement with Pfizer Inc

Business Wire, August 17, 2005

BOSTON -- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC announced that it served as counsel to Wellesley, MA-based Coley Pharmaceutical Group, Inc. (NASDAQ: COLY) in its initial public offering and a concurrent private placement with Pfizer Inc.

Coley's IPO consisted of 6,900,000 shares of common stock at a price of $16.00 per share, which included 900,000 shares issued upon exercise of the underwriters' over- allotment option. In a separate private placement, an additional 625,000 shares were purchased by Coley's collaboration partner, Pfizer, Inc., at $16.00 per share. Total proceeds from the IPO and private placement were $120.4 million, before commissions and expenses, with net proceeds at approximately $111.0 million.

Boston-based Mintz Levin attorneys William Whelan, Megan Gates, Christopher Denn, Linda Bentley, Michael Harrington, James Chicoski, Wendy Silverman, Marianne Staniunas and Linda Rockett represented Coley Pharmaceuticals in the transaction.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC is a multidisciplinary law firm with over 450 attorneys and senior professionals in Boston, Washington D.C., Reston, VA, New York, Stamford, CT, Los Angeles and London.

Mintz Levin is distinguished by its reputation for responsive client service and expertise in the areas of bankruptcy; business and finance; communications; employment; environmental; federal; health care; immigration; intellectual property; litigation; public finance; real estate; tax; and trusts and estates. Mintz Levin's international clientele range from privately held start-ups to Fortune 100 companies in a wide array of industries including biotechnology, venture capital, telecommunications, health care and high technology.

Mintz Levin was one of the first law firms to develop complementary consulting capabilities to provide complete solutions to clients' problems, including investment/wealth management, and government and public affairs. More information is available at www.mintz.com.

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases, asthma and allergy. Coley has established a pipeline of four TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Chiron, the United States government and GlaxoSmithKline.